MediMabBio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 19

MediMabBio General Information

Description

Developer of healthcare immunotherapies designed to treat serious diseases such as cancer and autoimmune disorders. The company offers engineered monoclonal antibodies, cytokine-antibody fusion proteins, and T-cell-targeted biologics, enabling pharmaceutical collaborators and clinical researchers to access next-generation immuno-oncology candidates and biologics with precision-designed functionalities.

Contact Information

Website
www.medimabbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Number 721, 54, Changeop-ro, Sujeong-gu
  • Seongnam, Gyeonggi 13449
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Number 721, 54, Changeop-ro, Sujeong-gu
  • Seongnam, Gyeonggi 13449
  • South Korea
+82

MediMabBio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MediMabBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Accelerator/Incubator 22-May-2026 Completed Startup
8. Later Stage VC (Series B) 27-Oct-2025 Completed Pre-Clinical Trials
7. Accelerator/Incubator 27-Aug-2024 Completed Pre-Clinical Trials
6. Later Stage VC 01-Jan-2024 Completed Pre-Clinical Trials
5. Early Stage VC (Series A) 10-Feb-2021 Completed Pre-Clinical Trials
4. Seed Round 15-Feb-2019 Completed Pre-Clinical Trials
3. Accelerator/Incubator 26-Jul-2017 Completed Pre-Clinical Trials
2. Seed Round 11-Jul-2017 Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view MediMabBio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

MediMabBio Patents

  • 24

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

MediMabBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025159595-A1 Anti-tigit antibody specifically binding to tigit, fusion protein comprising same and interleukin-10, and uses thereof Pending 24-Jan-2024
WO-2023239228-A1 Fusion protein comprising anti-tigit antibody, interleukin-15, and interleukin-15 receptor alpha sushi domain, and use thereof Inactive 10-Jun-2022
EP-4538290-A1 Fusion protein comprising antibody binding specifically to tigit and interleukin-15, and use thereof Pending 10-Jun-2022
EP-4538290-A4 Fusion protein comprising antibody binding specifically to tigit and interleukin-15, and use thereof Pending 10-Jun-2022
US-20260015417-A1 Fusion protein comprising antibody binding specifically to tigit and interleukin-15, and use thereof Pending 10-Jun-2022 C07K16/2803
To view MediMabBio’s complete patent history, request access »

MediMabBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MediMabBio Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
Korea Health Industry Development Institute Government
AON Investment Venture Capital Minority
DongBang FTL Corporation Minority
E&Venture Partners Venture Capital Minority
HLB bioStep Company Corporation Minority
You’re viewing 5 of 19 investors. Get the full list »

Ready to get started?

Request a free trial

MediMabBio FAQs

  • When was MediMabBio founded?

    MediMabBio was founded in 2017.

  • Where is MediMabBio headquartered?

    MediMabBio is headquartered in Seongnam, South Korea.

  • What is the size of MediMabBio?

    MediMabBio has 16 total employees.

  • What industry is MediMabBio in?

    MediMabBio’s primary industry is Drug Discovery.

  • Is MediMabBio a private or public company?

    MediMabBio is a Private company.

  • What is MediMabBio’s current revenue?

    The current revenue for MediMabBio is .

  • How much funding has MediMabBio raised over time?

    MediMabBio has raised $37.9M.

  • Who are MediMabBio’s investors?

    Korea Health Industry Development Institute, AON Investment, DongBang FTL, E&Venture Partners, and HLB bioStep Company are 5 of 19 investors who have invested in MediMabBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process